CHATHAM, N.J., June 02, 2022 (Globe NEWSWIRE) — Tonix Prescription drugs Holding Corp. (Nasdaq: TNXP), a medical-stage biopharmaceutical enterprise, declared today that it has regained compliance with the bare minimum bid price requirement for continued listing on The Nasdaq Cash Current market. On June 1, 2022, Tonix been given a letter from The Nasdaq Stock Market place LLC stating that for the reason that Tonix’s shares had a closing bid cost at or higher than $1.00 per share for a minimum of 10 consecutive small business days, Tonix’s stock had regained compliance with the least bid price tag requirement of $1.00 for each share for continued listing on The Nasdaq Cash Marketplace, as established forth in Nasdaq Listing Rule 5550(a)(2), and the make a difference is now closed.
About Tonix Pharmaceuticals Holding Corp.1
Tonix is a medical-stage biopharmaceutical corporation targeted on finding, licensing, buying and establishing therapeutics to address and protect against human condition and alleviate suffering. Tonix’s portfolio is composed of central anxious system (CNS), rare sickness, immunology and infectious disorder merchandise candidates. Tonix’s CNS portfolio consists of the two small molecules and biologics to handle agony, neurologic, psychiatric and habit situations. Tonix’s guide CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual pill), is in mid-Stage 3 growth for the management of fibromyalgia with a new Section 3 research released in the next quarter of 2022 and interim facts envisioned in the to start with quarter of 2023. TNX-102 SL is also currently being developed to handle Prolonged COVID, a long-term post-acute COVID-19 affliction. Tonix expects to initiate a Phase 2 review in Very long COVID in the 2nd quarter of 2022. TNX-1300 (cocaine esterase) is a biologic built to handle cocaine intoxication that is expected to commence a Section 2 trial in the next quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the Fda. At last, TNX-1900 (intranasal potentiated oxytocin), a modest molecule in advancement for persistent migraine, is anticipated to enter the clinic with a Section 2 examine in the 2nd half of 2022. Tonix’s unusual disease portfolio features TNX-2900 (intranasal potentiated oxytocin) for the therapy of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the Fda. Tonix’s immunology portfolio includes biologics to handle organ transplant rejection, autoimmunity and cancer, like TNX-1500 which is a humanized monoclonal antibody focusing on CD40-ligand becoming developed for the avoidance of allograft and xenograft rejection and for the remedy of autoimmune disorders. A Section 1 review of TNX-1500 is envisioned to be initiated in the 2nd 50 % of 2022. Tonix’s infectious disorder pipeline is composed of a vaccine in growth to avoid smallpox and monkeypox named TNX-801, up coming-era vaccines to prevent COVID-19, and a platform to make completely human monoclonal antibodies to deal with COVID-19. Tonix’s guide vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are stay virus vaccines primarily based on Tonix’s recombinant pox live virus vector vaccine platform.
1All of Tonix’s merchandise candidates are investigational new medicine or biologics and have not been approved for any indication.
This push release and additional information about Tonix can be observed at www.tonixpharma.com.
Ahead Looking Statements
Specific statements in this push release are forward-wanting within just the meaning of the Private Securities Litigation Reform Act of 1995. These statements could be recognized by the use of ahead-on the lookout text such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” between other folks. These forward-on the lookout statements are based on Tonix’s recent expectations and true benefits could differ materially. There are a number of things that could trigger real situations to differ materially from individuals indicated by this sort of forward-hunting statements. These variables include things like, but are not constrained to, dangers connected to the failure to obtain Fda clearances or approvals and noncompliance with Fda laws delays and uncertainties induced by the world wide COVID-19 pandemic risks relevant to the timing and progress of scientific advancement of our merchandise candidates our will need for further funding uncertainties of patent protection and litigation uncertainties of government or 3rd occasion payor reimbursement limited analysis and progress efforts and dependence upon third events and significant level of competition. As with any pharmaceutical below progress, there are major hazards in the improvement, regulatory acceptance and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking assertion. Traders should really study the hazard components established forth in the Yearly Report on Variety 10-K for the calendar year finished December 31, 2021, as submitted with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or following the day thereof. All of Tonix’s forward-searching statements are expressly capable by all these types of risk factors and other cautionary statements. The information established forth herein speaks only as of the day thereof.
Jessica Morris (company)
Olipriya Das, Ph.D. (media)
Peter Vozzo (traders)